|
|
Article: PathoGenesis Corp. Announces Results of Phase III Trials In Cystic Fibrosis Patients
- Article from:
- PR Newswire
- Article date:
- January 30, 1997
CopyrightCOPYRIGHT 1997 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
SEATTLE, Jan. 30 /PRNewswire/ -- PathoGenesis Corp. (Nasdaq: PGNS) today announced the results of its Phase III clinical trials of TOBI(TM) (tobramycin for inhalation) for treatment of chronic Pseudomonas aeruginosa lung infections in people with cystic fibrosis.
PathoGenesis conducted two double-blind, placebo-controlled Phase III clinical trials of its TOBI drug. A total of 468 patients in 69 cystic fibrosis care centers in the U.S. completed the trials. Treatment with the drug or a placebo was intermittent for six months, with patients on 300 mg. of aerosolized treatment twice daily for four weeks, then off therapy for four weeks. During the trials, ...